Yue Xiang Yue Health Submits IPO Prospectus in May 2026
Baheal Medical
Health Brand Commercialization Platform
ScieHome
Developer of Ultrasound Energy Technology and Pharmaceutical-Device Combination Technology
Trinomab
Developer of Natural Fully Human Monoclonal Antibody New Drugs
jifu Medical
Provider of R&D, Production, Sales, and Services for High-End Gastrointestinal Medical Products
Catug
One-stop CDMO Service Provider
Abogen
Nucleic Acid Drug Developer
Click to Follow? | Focused on Global Biopharmaceutical Investment
Since 2026, China’s capital markets have demonstrated resilience beyond expectations. In the first quarter, gross domestic product (GDP) grew by 5.0% year on year, surpassing market consensus; entering May, A-shares continued their strong performance, with the Shanghai Composite Index breaking through the 4,200-point mark to reach an eleven-year high. The resonance between macroeconomic data and market sentiment has created a rare window of opportunity for high-quality enterprises to pursue capital operations and business expansion.
Amid a Favorable Macro Environment, Multiple Portfolio Companies of Yifeng Capital Achieve Concentrated Financing Progress and Business Breakthroughs in May. From innovative drug development to high-end medical devices, multiple portfolio projects have successively achieved substantial progress at key milestones, including clinical advancement, product approvals, and subsequent financing rounds.
Biostar
· Secured Hundreds of Millions in Capital Increase, Introduced Strategic Shareholders
Biostar
· Secured Hundreds of Millions in Capital Increase, Introduced Strategic Shareholders
On May 8, Biostar announced that Baheal Medical had subscribed for 25 million new shares issued by Biostar.
ScieHome
· Secured Series A Funding to Build an Innovative Ultrasound Ecosystem Featuring “Ultrasound Energy, Drug-Ultrasound Synergy, and Precision Diagnosis and Treatment”
ScieHome
· Secured Series A Funding to Build an Innovative Ultrasound Ecosystem Featuring “Ultrasound Energy, Drug-Ultrasound Synergy, and Precision Diagnosis and Treatment”
Recently, ScieHome completed a Series A financing round of tens of millions of RMB. This roundThe financing was exclusively led by Yifeng Capital.
Trinomab
· Registration Draft of Prospectus: Accelerating Sprint to Capital Markets
On May 22, Trinomab submitted the registration version of its prospectus, accelerating its push into the capital markets.
Trinomab
· Registration Draft of Prospectus: Accelerating Sprint to Capital Markets
On May 22, Trinomab submitted the registration version of its prospectus, accelerating its push into the capital markets.
jifu Medical
· Debut at the 2026 Wuhu Health Conference and the 12th Jinling Health Forum
From May 22 to 24, the 2026 Wuhu Health Conference and the 12th “Jinling Health Forum” were held in Nanjing. jifu Medical showcased its independently developed capsule endoscopy system, MCS-170, at the conference.
Nurotron
· Diligent Practice and Continuous Improvement Forge New Global Heights for Nurotron
From May 10 to 13, the 18th International Conference on Cochlear Implants and Other Implantable Technologies was grandly held. Nurotron made a spectacular appearance with its latest research achievements and innovative products.
Catug
· CATUG Makes Appearance at European mRNA CMC Summit
From May 20 to 21, the 4th European mRNA Process Development and CMC Summit was held in Germany. Catug fully participated in this European summit.
· in collaboration with Suzhou Institute for Innovative Drug Research and Abogen BiosciencesmRNAAdvances in Vaccine Delivery
Recently, the team led by Professors Zhong Zhiyuan and Xu Congcong from the Suzhou Institute for Innovative Drugs, in collaboration with Professor Zhou Fangfang, Catug Biotechnology, and Abogen Biosciences (Suzhou), successfully developed TRAP, a transferrin receptor-mediated monocyte-targeted mRNA delivery platform.
· Debut at the ASGCT 2026 Annual Meeting in Boston
From May 11 to 15, the 29th Annual Meeting of the American Society of Gene & Cell Therapy was held in Boston. Dr. Wang Xiao, CEO of Catug, was invited to attend the roundtable forum at the satellite symposium.
Jingwei Shida
· 2026 Nanshan Respiratory Health Forum Held
May 30–31, 2026 Nanshan Respiratory Health Forum was held in Guangzhou. A special session was dedicated to sharing the clinical application value and latest achievements of the BIOPSEE® Beixi® probe-based confocal laser endomicroscopy for respiratory diseases, independently developed by Jingwei Shida.
HuiGuan Bio
· Debut at the "Optics + AI" Featured Exhibition Area of the 21st China International Optoelectronic Exposition
On May 18, the 21st “China Optics Valley” International Optoelectronics Expo kicked off in Wuhan. Huiguan Biology’s Light-Sheet 3D Digital-Intelligent Pathology Instrument was invited to be showcased in the “Optics + AI” featured exhibition area at this year’s event.
InnoMed
· Focusing on Innovative Applications of Surrogate Endpoints to Empower Efficient R&D of Novel Cardiorenal Drugs
From May 14 to 16, the DIA China Annual Meeting was held in Shanghai. Guo Shaohua, Vice President of Innovo Pharmaceuticals, attended the DIA China special sub-forum on “Innovation and Application of Surrogate Endpoints in Cardiovascular and Renal Drug Development.”
Tiangan Immunology
· Invited to Attend the 2026 Academic Conference of the Basic Immunology Branch of the Chinese Society for Immunology
From May 15 to 17, the 2026 Academic Conference of the Basic Immunology Branch of the Chinese Society for Immunology was held in Anhui Province. Professor Tian Zhigang, founder of Hefei Tiangang Immunology, was invited to attend and deliver a keynote address.
Pinshan Biotech
· Debut at the 25th China National Conference on Biological Products
Recently, the 25th China Biological Products Conference officially opened. Pinshan Biotechnology showcased its full product portfolio.
Coracle
· First Clinical Study on Domestically Produced Visualized Embolic Microspheres—TraSphere® Shanyuan® FIM Study Published in Prestigious Journal
Recently, Clarith’s independently developed world’s first visualized uniform-particle-size biomimetic core-shell embolic microspheres—Shanyuan® TraSphere®—achieved another milestone: its first-in-human study results in transarterial chemoembolization (TACE) for liver cancer were officially published in the authoritative journal Journal of Interventional Radiology.
· Published in Authoritative Journals
Recently, CareRay Medical announced another milestone: following the completion of the first pre-market randomized controlled trial (RCT) in China for its Ruiyuan® DiaSphere® embolic microspheres, the post-marketing clinical study paper was published on May 18 in the authoritative journal Journal of Interventional Radiology.
Aumo Pharma
· Shaoxing Municipal Party Committee Secretary Shi Huifang Conducts Research at Aomo Pharmaceutical’s Industrialization Base in Shaoxing Binhai New Area
jifu Medical
· Debut at the 2026 Wuhu Health Conference and the 12th Jinling Health Forum
From May 22 to 24, the 2026 Wuhu Health Conference and the 12th “Jinling Health Forum” were held in Nanjing. jifu Medical showcased its independently developed capsule endoscopy system, MCS-170, at the conference.
Nurotron
· Diligent Practice and Continuous Improvement Forge New Global Heights for Nurotron
From May 10 to 13, the 18th International Conference on Cochlear Implants and Other Implantable Technologies was grandly held. Nurotron made a spectacular appearance with its latest research achievements and innovative products.
Catug
· CATUG Makes Appearance at European mRNA CMC Summit
From May 20 to 21, the 4th European mRNA Process Development and CMC Summit was held in Germany. Catug fully participated in this European summit.
· in collaboration with Suzhou Institute for Innovative Drug Research and Abogen BiosciencesmRNAAdvances in Vaccine Delivery
Recently, the team led by Professors Zhong Zhiyuan and Xu Congcong from the Suzhou Institute for Innovative Drugs, in collaboration with Professor Zhou Fangfang, Catug Biotechnology, and Abogen Biosciences (Suzhou), successfully developed TRAP, a transferrin receptor-mediated monocyte-targeted mRNA delivery platform.
· Debut at the ASGCT 2026 Annual Meeting in Boston
From May 11 to 15, the 29th Annual Meeting of the American Society of Gene & Cell Therapy was held in Boston. Dr. Wang Xiao, CEO of Catug, was invited to attend the roundtable forum at the satellite symposium.
Jingwei Shida
· 2026 Nanshan Respiratory Health Forum Held
May 30–31, 2026 Nanshan Respiratory Health Forum was held in Guangzhou. A special session was dedicated to sharing the clinical application value and latest achievements of the BIOPSEE® Beixi® probe-based confocal laser endomicroscopy for respiratory diseases, independently developed by Jingwei Shida.
HuiGuan Bio
· Debut at the "Optics + AI" Featured Exhibition Area of the 21st China International Optoelectronic Exposition
On May 18, the 21st “China Optics Valley” International Optoelectronics Expo kicked off in Wuhan. Huiguan Biology’s Light-Sheet 3D Digital-Intelligent Pathology Instrument was invited to be showcased in the “Optics + AI” featured exhibition area at this year’s event.
InnoMed
· Focusing on Innovative Applications of Surrogate Endpoints to Empower Efficient R&D of Novel Cardiorenal Drugs
From May 14 to 16, the DIA China Annual Meeting was held in Shanghai. Guo Shaohua, Vice President of Innovo Pharmaceuticals, attended the DIA China special sub-forum on “Innovation and Application of Surrogate Endpoints in Cardiovascular and Renal Drug Development.”
Tiangan Immunology
· Invited to Attend the 2026 Academic Conference of the Basic Immunology Branch of the Chinese Society for Immunology
From May 15 to 17, the 2026 Academic Conference of the Basic Immunology Branch of the Chinese Society for Immunology was held in Anhui Province. Professor Tian Zhigang, founder of Hefei Tiangang Immunology, was invited to attend and deliver a keynote address.
Pinshan Biotech
· Debut at the 25th China National Conference on Biological Products
Recently, the 25th China Biological Products Conference officially opened. Pinshan Biotechnology showcased its full product portfolio.
Coracle
· First Clinical Study on Domestically Produced Visualized Embolic Microspheres—TraSphere® Shanyuan® FIM Study Published in Prestigious Journal
Recently, Clarith’s independently developed world’s first visualized uniform-particle-size biomimetic core-shell embolic microspheres—Shanyuan® TraSphere®—achieved another milestone: its first-in-human study results in transarterial chemoembolization (TACE) for liver cancer were officially published in the authoritative journal Journal of Interventional Radiology.
· Published in Authoritative Journals
jifu Medical
· Debut at the 2026 Wuhu Health Conference and the 12th Jinling Health Forum
jifu Medical
· Debut at the 2026 Wuhu Health Conference and the 12th Jinling Health Forum
From May 22 to 24, the 2026 Wuhu Health Conference and the 12th “Jinling Health Forum” were held in Nanjing. jifu Medical showcased its independently developed capsule endoscopy system, MCS-170, at the conference.
Nurotron
· Diligent Practice and Continuous Improvement Forge New Global Heights for Nurotron
Nurotron
· Diligent Practice and Continuous Improvement Forge New Global Heights for Nurotron
From May 10 to 13, the 18th International Conference on Cochlear Implants and Other Implantable Technologies was grandly held. Nurotron made a spectacular appearance with its latest research achievements and innovative products.
Catug
· CATUG Makes Appearance at European mRNA CMC Summit
Catug
· CATUG Makes Appearance at European mRNA CMC Summit
From May 20 to 21, the 4th European mRNA Process Development and CMC Summit was held in Germany. Catug fully participated in this European summit.
· in collaboration with Suzhou Institute for Innovative Drug Research and Abogen BiosciencesmRNAAdvances in Vaccine Delivery
Recently, the team led by Professors Zhong Zhiyuan and Xu Congcong from the Suzhou Institute for Innovative Drugs, in collaboration with Professor Zhou Fangfang, Catug Biotechnology, and Abogen Biosciences (Suzhou), successfully developed TRAP, a transferrin receptor-mediated monocyte-targeted mRNA delivery platform.
· Debut at the ASGCT 2026 Annual Meeting in Boston
From May 11 to 15, the 29th Annual Meeting of the American Society of Gene & Cell Therapy was held in Boston. Dr. Wang Xiao, CEO of Catug, was invited to attend the roundtable forum at the satellite symposium.
Jingwei Shida
· 2026 Nanshan Respiratory Health Forum Held
Jingwei Shida
· 2026 Nanshan Respiratory Health Forum Held
May 30–31, 2026 Nanshan Respiratory Health Forum was held in Guangzhou. A special session was dedicated to sharing the clinical application value and latest achievements of the BIOPSEE® Beixi® probe-based confocal laser endomicroscopy for respiratory diseases, independently developed by Jingwei Shida.
HuiGuan Bio
· Debut at the "Optics + AI" Featured Exhibition Area of the 21st China International Optoelectronic Exposition
HuiGuan Bio
· Debut at the "Optics + AI" Featured Exhibition Area of the 21st China International Optoelectronic Exposition
On May 18, the 21st “China Optics Valley” International Optoelectronics Expo kicked off in Wuhan. Huiguan Biology’s Light-Sheet 3D Digital-Intelligent Pathology Instrument was invited to be showcased in the “Optics + AI” featured exhibition area at this year’s event.
InnoMed
· Focusing on Innovative Applications of Surrogate Endpoints to Empower Efficient R&D of Novel Cardiorenal Drugs
InnoMed
· Focusing on Innovative Applications of Surrogate Endpoints to Empower Efficient R&D of Novel Cardiorenal Drugs
From May 14 to 16, the DIA China Annual Meeting was held in Shanghai. Guo Shaohua, Vice President of Innovo Pharmaceuticals, attended the DIA China special sub-forum on “Innovation and Application of Surrogate Endpoints in Cardiovascular and Renal Drug Development.”
Tiangan Immunology
· Invited to Attend the 2026 Academic Conference of the Basic Immunology Branch of the Chinese Society for Immunology
Tiangan Immunology
· Invited to Attend the 2026 Academic Conference of the Basic Immunology Branch of the Chinese Society for Immunology
From May 15 to 17, the 2026 Academic Conference of the Basic Immunology Branch of the Chinese Society for Immunology was held in Anhui Province. Professor Tian Zhigang, founder of Hefei Tiangang Immunology, was invited to attend and deliver a keynote address.
Pinshan Biotech
· Debut at the 25th China National Conference on Biological Products
Pinshan Biotech
· Debut at the 25th China National Conference on Biological Products
Recently, the 25th China Biological Products Conference officially opened. Pinshan Biotechnology showcased its full product portfolio.
Coracle
· First Clinical Study on Domestically Produced Visualized Embolic Microspheres—TraSphere® Shanyuan® FIM Study Published in Prestigious Journal
Coracle
· First Clinical Study on Domestically Produced Visualized Embolic Microspheres—TraSphere® Shanyuan® FIM Study Published in Prestigious Journal
Recently, Clarith’s independently developed world’s first visualized uniform-particle-size biomimetic core-shell embolic microspheres—Shanyuan® TraSphere®—achieved another milestone: its first-in-human study results in transarterial chemoembolization (TACE) for liver cancer were officially published in the authoritative journal Journal of Interventional Radiology.
· Published in Authoritative Journals
· Published in Authoritative Journals
Recently, CareRay Medical announced another milestone: following the completion of the first pre-market randomized controlled trial (RCT) in China for its Ruiyuan® DiaSphere® embolic microspheres, the post-marketing clinical study paper was published on May 18 in the authoritative journal Journal of Interventional Radiology.
Aumo Pharma
· Shaoxing Municipal Party Committee Secretary Shi Huifang Conducts Research at Aomo Pharmaceutical’s Industrialization Base in Shaoxing Binhai New Area
Aumo Pharma
· Shaoxing Municipal Party Committee Secretary Shi Huifang Conducts Research at Aomo Pharmaceutical’s Industrialization Base in Shaoxing Binhai New Area
On May 7, Shi Huifang, Secretary of the Shaoxing Municipal Committee of the Communist Party of China, and his delegation visited Aomo Pharmaceutical’s Aopu Innovative Drug Production Base in the Binhai New Area to conduct an on-site investigation into the progress of project construction.
Hannuo Medical
· Joining Hands with Global Experts to Explore the Clinical Boundaries of ECMO
Hannuo Medical
· Joining Hands with Global Experts to Explore the Clinical Boundaries of ECMO
Hannuo Medical
· Joining Hands with Global Experts to Explore the Clinical Boundaries of ECMO
Hannuo Medical
· Joining Hands with Global Experts to Explore the Clinical Boundaries of ECMO
From May 7 to 9, EuroELSO 2026 was held in Ireland. Hanuo Medical once again showcased its Lifemotion® ECMO system at this year’s EuroELSO and delivered two specialized academic symposia centered on the theme “ECMO Beyond the Rules.”
Trinomab
· Partnering with the ESG Rescue Alliance
Trinomab
· Partnering with the ESG Rescue Alliance
Trinomab
· Partnering with the ESG Rescue Alliance
Trinomab
· Partnering with the ESG Rescue Alliance
On May 12, Trinomab officially signed the “Cooperation Agreement on Corporate Social Responsibility (ESG) Participation in the Yunnan Provincial Disaster Relief Alliance” at the Disaster Preparedness and Relief Center of the Yunnan Provincial Red Cross Society, joining the Yunnan Provincial Disaster Relief ESG Alliance.
Zhongmou Medical
· Showcasing Clinical Translation Achievements and Next-Generation Retinal Gene Therapy Platforms at ASGCT 2026
Zhongmou Medical
· Showcasing Clinical Translation Achievements and Next-Generation Retinal Gene Therapy Platforms at ASGCT 2026
Zhongmou Medical
· Showcasing Clinical Translation Achievements and Next-Generation Retinal Gene Therapy Platforms at ASGCT 2026
Zhongmou Medical
· Showcasing Clinical Translation Achievements and Next-Generation Retinal Gene Therapy Platforms at ASGCT 2026
Recently, Zhongmou Medical delivered two oral presentations and one poster presentation at the 2026 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held in Boston.
Huamei Haolian
· “AI + Health Management” Becomes the Core Engine for Upgrading the Medical Ecosystem
Huamei Haolian
· “AI + Health Management” Becomes the Core Engine for Upgrading the Medical Ecosystem
Huamei Haolian
· “AI + Health Management” Becomes the Core Engine for Upgrading the Medical Ecosystem
Huamei Haolian
· “AI + Health Management” Becomes the Core Engine for Upgrading the Medical Ecosystem
On May 9, the sub-forum “New Talk AI Think Tank” of the 2026 World Brand Moganshan Conference was held in Zhejiang. Xu Bingyu, Founder and CEO of Huamei Haolian, delivered a keynote speech titled “AI + Big Health Service Innovation Practice.”
· Attending the Wujiang Venture Capital 2026 Annual Conference
May 18–19, Wujiang Venture Capital 2026 Spring Partners Meeting Held in Ningbo, Huamei HaolianFounder, CEOXu Bingyu was invited to attend the roundtable forum titled “AI Empowering the Real Economy: Implementation Opportunities, Barrier Construction, and Regional Ecosystem Cultivation.”
Ailios
· Debut at INTERPHEX WEEK 2026
· Attending the Wujiang Venture Capital 2026 Annual Conference
May 18–19, Wujiang Venture Capital 2026 Spring Partners Meeting Held in Ningbo, Huamei HaolianFounder, CEOXu Bingyu was invited to attend the roundtable forum titled “AI Empowering the Real Economy: Implementation Opportunities, Barrier Construction, and Regional Ecosystem Cultivation.”
Ailios
· Debut at INTERPHEX WEEK 2026
· Attending the Wujiang Venture Capital 2026 Annual Conference
May 18–19, Wujiang Venture Capital 2026 Spring Partners Meeting Held in Ningbo, Huamei HaolianFounder, CEOXu Bingyu was invited to attend the roundtable forum titled “AI Empowering the Real Economy: Implementation Opportunities, Barrier Construction, and Regional Ecosystem Cultivation.”
· Attending the Wujiang Venture Capital 2026 Annual Conference
May 18–19, Wujiang Venture Capital 2026 Spring Partners Meeting Held in Ningbo, Huamei HaolianFounder, CEOXu Bingyu was invited to attend the roundtable forum titled “AI Empowering the Real Economy: Implementation Opportunities, Barrier Construction, and Regional Ecosystem Cultivation.”
Ailios
· Debut at INTERPHEX WEEK 2026
Ailios
· Debut at INTERPHEX WEEK 2026
May 20–22: Japan International Pharmaceutical Industry Exhibition Opens in Tokyo. Elios Showcases Comprehensive Pharmaceutical Filtration Process Solutions.
Vima Medical
· “Hand-Eye-Brain” Collaborative Interventional Diagnosis and Treatment Solution Shines in Paris
Vima Medical
· “Hand-Eye-Brain” Collaborative Interventional Diagnosis and Treatment Solution Shines in Paris
Vima Medical
· “Hand-Eye-Brain” Collaborative Interventional Diagnosis and Treatment Solution Shines in Paris
Vima Medical
· “Hand-Eye-Brain” Collaborative Interventional Diagnosis and Treatment Solution Shines in Paris
From May 19 to 22, EuroPCR 2026 officially opened in Paris. Weimai Medical made its official debut with its core products, the ETcath® interventional surgical robot and its full line of DSA angiography systems.
· The First Affiliated Hospital of Xi'an Jiaotong University utilizes Weimai Medical
Recently, the team led by President Yuan Zuyi of the First Affiliated Hospital of Xi’an Jiaotong University successfully performed surgery for high-risk complex coronary bifurcation lesions using a domestically produced interventional robot from Weimai Medical.
· “First-Set” Hard Power, Ushering in a New Era of Precision Medicine
Recently, the 28th China Beijing International High-Tech Expo successfully concluded at the China National Convention Center. Weimai Medical made a significant appearance with its ETcath® interventional surgical robot.
3D Medicines
· Envida® Phase III Clinical Study in Neoadjuvant/Adjuvant Treatment of Non-Small Cell Lung Cancer Has Completed Enrollment Ahead of Schedule
On May 21, 3D Medicines announced that patient enrollment has been completed ahead of schedule for the randomized, controlled, double-blind, multicenter Phase III clinical study evaluating its commercialized product, Envafert® (envafolimab injection), for neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer (NSCLC).
WuYuan Biologics
· “Case Report on the Perioperative Application of Aofumin®” Published in Chinese Journal of New Drugs
Recently, Professor Yang Zhiyong’s team from the Department of Hepatobiliary and Pancreatic Surgery at Zhongnan Hospital of Wuhan University published a case report on the perioperative application of the world’s first plant-derived recombinant human albumin injection (Huiyan Bio’s Aofumin®) in Chinese Journal of New Drugs.
Biostar
· Four Clinical Study Abstracts Featured at ASCO 2026
· The First Affiliated Hospital of Xi'an Jiaotong University utilizes Weimai Medical
Recently, the team led by President Yuan Zuyi of the First Affiliated Hospital of Xi’an Jiaotong University successfully performed surgery for high-risk complex coronary bifurcation lesions using a domestically produced interventional robot from Weimai Medical.
· “First-Set” Hard Power, Ushering in a New Era of Precision Medicine
Recently, the 28th China Beijing International High-Tech Expo successfully concluded at the China National Convention Center. Weimai Medical made a significant appearance with its ETcath® interventional surgical robot.
3D Medicines
· Envida® Phase III Clinical Study in Neoadjuvant/Adjuvant Treatment of Non-Small Cell Lung Cancer Has Completed Enrollment Ahead of Schedule
On May 21, 3D Medicines announced that patient enrollment has been completed ahead of schedule for the randomized, controlled, double-blind, multicenter Phase III clinical study evaluating its commercialized product, Envafert® (envafolimab injection), for neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer (NSCLC).
WuYuan Biologics
· “Case Report on the Perioperative Application of Aofumin®” Published in Chinese Journal of New Drugs
Recently, Professor Yang Zhiyong’s team from the Department of Hepatobiliary and Pancreatic Surgery at Zhongnan Hospital of Wuhan University published a case report on the perioperative application of the world’s first plant-derived recombinant human albumin injection (Huiyan Bio’s Aofumin®) in Chinese Journal of New Drugs.
Biostar
· Four Clinical Study Abstracts Featured at ASCO 2026
· The First Affiliated Hospital of Xi'an Jiaotong University utilizes Weimai Medical
Recently, the team led by President Yuan Zuyi of the First Affiliated Hospital of Xi’an Jiaotong University successfully performed surgery for high-risk complex coronary bifurcation lesions using a domestically produced interventional robot from Weimai Medical.
· “First-Set” Hard Power, Ushering in a New Era of Precision Medicine
Recently, the 28th China Beijing International High-Tech Expo successfully concluded at the China National Convention Center. Weimai Medical made a significant appearance with its ETcath® interventional surgical robot.
3D Medicines
· Envida® Phase III Clinical Study in Neoadjuvant/Adjuvant Treatment of Non-Small Cell Lung Cancer Has Completed Enrollment Ahead of Schedule
3D Medicines
· Envida® Phase III Clinical Study in Neoadjuvant/Adjuvant Treatment of Non-Small Cell Lung Cancer Has Completed Enrollment Ahead of Schedule
3D Medicines
· Envida® Phase III Clinical Study in Neoadjuvant/Adjuvant Treatment of Non-Small Cell Lung Cancer Has Completed Enrollment Ahead of Schedule
On May 21, 3D Medicines announced that patient enrollment has been completed ahead of schedule for the randomized, controlled, double-blind, multicenter Phase III clinical study evaluating its commercialized product, Envafert® (envafolimab injection), for neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer (NSCLC).
WuYuan Biologics
· “Case Report on the Perioperative Application of Aofumin®” Published in Chinese Journal of New Drugs
WuYuan Biologics
· “Case Report on the Perioperative Application of Aofumin®” Published in Chinese Journal of New Drugs
WuYuan Biologics
· “Case Report on the Perioperative Application of Aofumin®” Published in Chinese Journal of New Drugs
WuYuan Biologics
· “Case Report on the Perioperative Application of Aofumin®” Published in Chinese Journal of New Drugs
Recently, Professor Yang Zhiyong’s team from the Department of Hepatobiliary and Pancreatic Surgery at Zhongnan Hospital of Wuhan University published a case report on the perioperative application of the world’s first plant-derived recombinant human albumin injection (Huiyan Bio’s Aofumin®) in Chinese Journal of New Drugs.
Biostar
· Four Clinical Study Abstracts Featured at ASCO 2026
Biostar
· Four Clinical Study Abstracts Featured at ASCO 2026
Recently, ASCO 2026 was held in the United States. Four latest clinical study data sets of Biostar’s core products, Utidelone Capsules and Utidelone Injection, were presented in the form of posters.
Huayuan Regeneration
· World’s First iPSC-Derived Renal Cell Therapy Product Approved for Clinical Trials
On May 14, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced on its official website that the first indication for “Human-derived Renal Progenitor Cell Injection (ARM101),” submitted by Huayue Nephrology, a wholly-owned subsidiary of Huayuan Regenerative Medicine, has been approved for clinical trials.
Lingyi Biotech
· IND Application for LY-M003 Injection, a Gene Therapy Drug for Hepatolenticular Degeneration, Receives Implicit Approval from the National Medical Products Administration
Huayuan Regeneration
· World’s First iPSC-Derived Renal Cell Therapy Product Approved for Clinical Trials
On May 14, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced on its official website that the first indication for “Human-derived Renal Progenitor Cell Injection (ARM101),” submitted by Huayue Nephrology, a wholly-owned subsidiary of Huayuan Regenerative Medicine, has been approved for clinical trials.
Lingyi Biotech
· IND Application for LY-M003 Injection, a Gene Therapy Drug for Hepatolenticular Degeneration, Receives Implicit Approval from the National Medical Products Administration
Huayuan Regeneration
· World’s First iPSC-Derived Renal Cell Therapy Product Approved for Clinical Trials
Huayuan Regeneration
· World’s First iPSC-Derived Renal Cell Therapy Product Approved for Clinical Trials
Huayuan Regeneration
· World’s First iPSC-Derived Renal Cell Therapy Product Approved for Clinical Trials
On May 14, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced on its official website that the first indication for “Human-derived Renal Progenitor Cell Injection (ARM101),” submitted by Huayue Nephrology, a wholly-owned subsidiary of Huayuan Regenerative Medicine, has been approved for clinical trials.
Lingyi Biotech
· IND Application for LY-M003 Injection, a Gene Therapy Drug for Hepatolenticular Degeneration, Receives Implicit Approval from the National Medical Products Administration
Lingyi Biotech
· IND Application for LY-M003 Injection, a Gene Therapy Drug for Hepatolenticular Degeneration, Receives Implicit Approval from the National Medical Products Administration
On May 9, Lingyi Biologics announced that its independently developed gene therapy drug for Wilson’s disease, LY-M003 injection, has officially received implicit approval from the National Medical Products Administration (NMPA) for an Investigational New Drug (IND) application as a Class I therapeutic biological product.
Awarded [[Arterial Network] 2026Future Healthcare Top 100: Innovative Devices and Intelligent Manufacturing TOP 100
· Vimai Medical, Tingsheng Technology, jifu Medical, Ruijing Biotechnology
Awarded [[Arterial Network] 2026Future Healthcare Top 100: Innovative Devices and Intelligent Manufacturing TOP 100
· Vimai Medical, Tingsheng Technology, jifu Medical, Ruijing Biotechnology
Honored with the TOP 100 on [VBData] 2026 Future Healthcare 100 List for Innovative Pharmaceuticals and Biological Products
· Trinomab, Zhongsheng Ruichuang, New Element Pharmaceutical, Aumo Pharma, Pulai Medical, Gaoguang Pharmaceutical, Dingchi Biotech, Bendao Gene, Lingyi Biotech
Honored with the TOP 100 on [VBData] 2026 Future Healthcare 100 List for Innovative Pharmaceuticals and Biological Products
Honored with the TOP 100 on [VBData] 2026 Future Healthcare 100 List for Innovative Pharmaceuticals and Biological Products
· Trinomab, Zhongsheng Ruichuang, New Element Pharmaceutical, Aumo Pharma, Pulai Medical, Gaoguang Pharmaceutical, Dingchi Biotech, Bendao Gene, Lingyi Biotech
Honored to be listed in the [VCBeat] 2026 Future Healthcare 100 – Top 100 Innovative Health Services and Industry Chain Services
Honored to be listed in the [VCBeat] 2026 Future Healthcare 100 – Top 100 Innovative Health Services and Industry Chain Services
· Baijun Biotech, Catug, AiliOs
· Baijun Biotech, Catug, AiliOs
RongAwarded[PharmaCube] Top 15 Business Development Deals for Innovative Drugs in China in 2025
RongAwarded[PharmaCube] Top 15 Business Development Deals for Innovative Drugs in China in 2025
· Harbour BioMed, Quanxin Biologics
· Harbour BioMed, Quanxin Biologics
RongAwarded[PharmCube] Top 15 High-Quality Frontier Innovation Achievements in China's Innovative Drugs for 2025
RongAwarded[PharmCube] Top 15 High-Quality Frontier Innovation Achievements in China's Innovative Drugs for 2025
· RingCode Biotech
· RingCode Biotech
RongObtained【PharmaCube】Top 30 Chinese Innovative Drugs with International Competitiveness in 2025
RongObtained【PharmaCube】Top 30 Chinese Innovative Drugs with International Competitiveness in 2025
· Ascentage Pharma, Harbour BioMed
· Ascentage Pharma, Harbour BioMed
RongAwarded【VB100】2026 Future Healthcare 100 · Person Award – 50 Most Influential Innovators in China’s Healthcare Industry
RongAwarded【VB100】2026 Future Healthcare 100 · Person Award – 50 Most Influential Innovators in China’s Healthcare Industry
· Dr. Huaixin Liao, Co-founder, Chairman, and Chief Technology Officer of Trinomab
· Dr. Huaixin Liao, Co-founder, Chairman, and Chief Technology Officer of Trinomab
Named Among the Top 10 Advances in Chinese Pharmaceutical Biotechnology in 2025
Named Among the Top 10 Advances in Chinese Pharmaceutical Biotechnology in 2025
· Wuhan HealthGene Biopharmaceutical Co., Ltd. Aofumin®
· Wuhan HealthGene Biopharmaceutical Co., Ltd. Aofumin®
Honored as One of the Top 50 Pre-Unicorn Companies in China for 2025-2026 by [Rongzhong]
Honored as One of the Top 50 Pre-Unicorn Companies in China for 2025-2026 by [Rongzhong]
· Shengsi Biotech
· Shengsi Biotech
Yifeng Capital -
Top 30 Most Active Venture Capital Firms in China in Q1 2026
Top 10 Most Active Healthcare Investment Firms in Q1 2026
Zhu Pai, CEO of Yifeng Capital -
2026 China's Best Young Investment Figures
✦
Recommended Reading
✦
NorthLife's IPO on the STAR Market
✦
Recommended Reading
✦
NorthLife's IPO on the STAR Market
NorthLife's IPO on the STAR Market
Wuhan Huiyuan Biological Co., Ltd. IPO on the STAR Market
Bokang Shiyun's IPO on the Main Board of the Hong Kong Stock Exchange
Shenghe Biotechnology's Main Board IPO in Hong Kong
Quanxin Biotech’s Main Board IPO in Hong Kong
Moving Upstream, Advancing with Time
3D Medicines’ IPO on the Main Board of the Hong Kong Stock Exchange
Obio Technology's IPO on the STAR Market
Ten Years Honing the Sword, Unsheathed with Razor Sharpness
Yahong Medicine's STAR Market IPO
Looking forward to your
Share
Like
Watching
Wuhan Huiyuan Biological Co., Ltd. IPO on the STAR Market
Wuhan Huiyuan Biological Co., Ltd. IPO on the STAR Market
Wuhan Huiyuan Biological Co., Ltd. IPO on the STAR Market
Bokang Shiyun's IPO on the Main Board of the Hong Kong Stock Exchange
Bokang Shiyun's IPO on the Main Board of the Hong Kong Stock Exchange
Shenghe Biotechnology's Main Board IPO in Hong Kong
Quanxin Biotech’s Main Board IPO in Hong Kong
Moving Upstream, Advancing with Time
3D Medicines’ IPO on the Main Board of the Hong Kong Stock Exchange
Obio Technology's IPO on the STAR Market
Ten Years Honing the Sword, Unsheathed with Razor Sharpness
Yahong Medicine's STAR Market IPO
Looking forward to your
Share
Like
Watching